author-photo

Eric Lawitz

University of Texas Health Science Center at San Antonio
University of Texas at Austin

508

Papers

27628

Citations

Citation Trend

Filter By

Papers (336) Sort By

Journal Conference Others

848 A NOVEL, PRECISION-ENGINEERED AMINO ACID COMPOSITION, AXA1665, IS SAFE, WELL-TOLERATED AND IMPROVES NEUROCOGNITION AND PHYSICAL FUNCTION IN CHILD-PUGH A AND B SUBJECTS

2021 Gastroenterology
Show All
- Source
- Cite
- Save
Citations (0)
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.

2021 The American Journal of Gastroenterology
Show All
- Source
- Cite
- Save
Citations (0)
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.

2021 Journal of Hepatology
Show All
- Source
- Cite
- Save
Citations (0)
Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis

2021 Hepatology
Show All
- Source
- Cite
- Save
Citations (0)
BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.

2021 Hepatology
Show All
- Source
- Cite
- Save
Citations (0)
BIO89-100 Demonstrated Robust Reductions in Liver Fat and Liver Fat Volume (LFV) by MRI-PDFF, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH

2021 Journal of the Endocrine Society
Show All
- Source
- Cite
- Save
Citations (0)
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.

2021 Hepatology
Show All
- Source
- Cite
- Save
Citations (11)
Tu1695 HEALTH OUTCOMES OVER 6 MONTHS IN 907 PATIENTS WITH HEPATIC ENCEPHALOPATHY TREATED IN COMMUNITY PRACTICE USING A SPECIALIZED PHARMACY TEAM

2020 Gastroenterology
Show All
- Source
- Cite
- Save
Citations (0)
1850-P: High Prevalence of Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH): The Impact on Patient-Reported Outcomes (PROs)

2020 Diabetes
Show All
- Source
- Cite
- Save
Citations (0)
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study

2020
Show All
- Source
- Cite
- Save
Citations (1)